Haemonetics announces updates to its Executive Leadership team

Haemonetics (HAE) announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, COO on April 7, and Roy Galvin has been appointed as the company’s Executive Vice President, Chief Commercial Officer, effective immediately. With more than 25 years of experience in medical device and healthcare technology leadership, Chan has successfully delivered innovative solutions to market, expanded patient access with global market development, and led business transformation initiatives across large organizations. He joins Haemonetics from Medtronic (MDT), where he served as President of Acute Care & Monitoring, overseeing a global portfolio of airway management, patient monitoring, and connected care solutions. Galvin joined Haemonetics in 2022 as President, Global Plasma and Blood Center. As Chief Commercial Officer, he will now have responsibility for the company’s Global Hospital business as well as Global Plasma and Blood Center, directing all commercialization initiatives to expand the reach and breadth of Haemonetics’ full product portfolio. Galvin brings to the role extensive experience in the global healthcare technology field for hospitals and the surgical suite, with over 25 years working at Medtronic plc scaling businesses in the Neuroscience and Orthopedic markets.